ReviewFrontiers in molecular biosciences2025
Recent advances in applications of artificial intelligence-assisted Raman spectroscopy in diagnosis of cancers.
Review in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glycomic Insights in Gynecological Disease: From Molecular Mechanisms to Precision Diagnostics and Therapeutics.International journal of molecular sciences · 2026Review
- Raman and surface-enhanced Raman spectroscopy for intraoperative cancer diagnostics: sentinel lymph node biopsy, biomarkers and translational challenges.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of death worldwide. Among various diagnostic approaches, Raman spectroscopy (RS) has emerged as an advanced detection technology with the potential to distinguish cancerous tissues from normal ones. Notably, RS has been verified to show improved sensitivity, specificity, and accuracy for cancer diagnosis compared to conventional techniques. Recently, artificial intelligence (AI), developed to emulate human capabilities, has gained enough popularity and showcased its strength in learning high-level representations and recognizing complex patterns with remarkable efficiency. In this context, AI-assisted RS has been applied to the classification and prediction of cancer cells, achieving a higher accuracy of ∼90% in correct predictions from a single spectrum. However, there has been no comprehensive review about the use of AI-assisted RS in distinguishing different types of cancer cells. Although AI-assisted RS has been widely utilized by researchers and clinicians over the past a few years to diagnose various cancers, including gastrointestinal, head and neck, cervical, and endocrine-related cancers, an in-depth investigation has yet to be conducted. This review aims to provide a narrative overview of the latest applications of AI-assisted RS in cancer diagnosis, summarize the key findings and benefits, discuss the associated challenges in different types of cancers, and present additional studies on AI-assisted RS in non-cancer diseases, such as fungal infections. Through this review, we hope to enhance researchers' understanding of the potential value of AI-assisted RS in both cancer and non-cancer diseases, presenting a new diagnostic approach for clinical management, optimizing diagnostic efficacy, and ultimately improving patient survival outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.